Even mild levels of kidney dysfunction affected the levels of several blood-based biomarkers for Alzheimer’s disease.
Older adults experiencing dual decline are at greater risk of developing dementia than those with changes in only one area.
Most people whose brains exhibit Alzheimer’s pathology don’t have the disease; they reach the end of their lives never having exhibited cognitive impairment. A new study examines the genetics of this resilience.
The announcement of the recognition of VMAC as an NIH Center of Excellence comes nearly five years after the creation of an exploratory NIA-funded Alzheimer’s Disease Research Center.
Data from more than 4,000 participants reveals link between brain structure and cognitive decline.
Santisteban’s research project will investigate whether the renin angiotensin system plays an important role in the progression of pathology in Alzheimer’s disease.